Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.
Anushka Bhaskar, MPhil
Advertisement
Articles by Anushka Bhaskar, MPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5
